Cosmetic cross-reference

Ornithine

CAS 70-26-8

Ornithine (CAS 70-26-8) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 20 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Ornithine

CAS Number

70-26-8

UNII

E524N2IXA3

InChIKey

AHLPHDHHMVZTML-BYPYZUCNSA-N

ChEMBL ID

CHEMBL446143

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL446143 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	30000 nM	31	-
G-protein coupled receptor family C group 6 member A GPCR	EC50	4	-	Homo sapiens

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
GPRC6 GPRC6A	Full agonist	4.0 pEC50	15576628

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ornithine used for in pharmaceutical contexts?

Ornithine (CAS 70-26-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ornithine?

Ornithine has 20 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Acute kidney injury, Cardiac arrest, Exposure during pregnancy, Injection site pain, Multiple organ dysfunction syndrome. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ornithine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ornithine with EU status "permitted".

What clinical phase is Ornithine in?

Ornithine is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Ornithine?

Ornithine has 2 bioactivity rows in this page query. Rendered target entries include G-protein coupled receptor family C group 6 member A.